Foley Hoag Represents Pear Therapeutics in $20M Series D Extension

March 5, 2021

Foley Hoag LLP represented Pear Therapeutics, Inc., a pioneer of prescription digital therapeutics (PDTs), in the extension of its Series D financing, which included a leading national Integrated Delivery Network (IDN) as a new strategic investor. The national IDN invested $20 million, bringing the total Series D investment to $100 million. Pear is using its Series D financing to accelerate reimbursement coverage for its three FDA-authorized products, creating the first market access pathway in the PDT industry. 

With offices in Boston, MA, Research Triangle, NC and San Francisco, CA, Pear aims to redefine medicine by discovering, developing and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. The company has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. 

Foley Hoag attorneys David Broadwin, Jennifer Lichtman, Anna Snook and Alexandra Bender represented Pear in the transaction. 

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.